

# CellCyte Genetics Corporation and The Fred Hutchinson Cancer Research Center Sign a Beta Test Collaboration Agreement to Evaluate CellCyte's CCG-E45 Culture Chamber

October 4, 2010, 9:15 am ET

Bellevue, Wash., October 4, 2010 BusinessWire -- CellCyte Genetics Corporation (OTCBB: CCYG - News) announced today that the Company has signed a beta test collaboration agreement with the Fred Hutchinson Cancer Research Center in Seattle, Washington, to evaluate the effectiveness of CellCyte's CCG-E45 Culture Chamber product as a supplement or replacement to their current methods of culturing specific cell lines.

Shelly Heimfeld, Ph.D., Director of the Cellular Therapy Laboratory and cGMP Cell Processing Facility at the Fred Hutchinson Cancer Research Center will lead the team that will evaluate the use of the CCG-E45 Culture Chamber in their cord blood and T-cell culture systems. Douglas P. Cerretti Ph.D., CellCyte's President and Chief Science Officer explains "Laboratory researchers, using CellCyte's CGC-E45 cell expansion technology can potentially reduce the labor hours and floor space required and many of the contamination risks that are typical of other cell expansion techniques. We look forward to working with researchers at the Fred Hutchinson Cancer Research Center to assist them in achieving the full range of benefits to be derived by using CellCyte's CCG-E45 Culture Chamber and Incubator.

"CellCyte is very pleased to establish this collaboration with the Fred Hutchinson Cancer Research Center. If proven effective with the cell culture systems with which the Hutchinson is working, the researchers should realize a substantial increase in laboratory productivity." said John M. Fluke Jr., Chairman of the Board of Directors.

CellCyte's CCG-E45 Culture Chamber is a cell expansion device that allows the culture of cells at high density and under precisely controlled oxygenation, providing an alternative to standard cell culture methodologies. CellCyte is seeking additional collaborative relationships with other independent clinical research laboratories to apply this technology to a wide range of cell expansion applications.

## About CellCyte Genetics:

CellCyte Genetics (OTC Symbol CCYG) is an emerging biotechnology company engaged in the discovery, development and commercialization of products that enhance the productivity of biotechnology research laboratories. The Company's initial product line is comprised of the CCG-E45 Culture Chamber and related CCG-E45 Incubator which have been in experimental use for the last several years. For clinical research laboratories, the CCG-E45 technology holds the potential to improve cell expansion labor costs and equipment utilization while significantly reducing the risk of contamination and the consequential elapsed time delays.

For further information see: [www.cellcyte.com](http://www.cellcyte.com) or contact Randy Lieber, CFO at 424-519-3775 or at [randy.lieber@cellcyte.com](mailto:randy.lieber@cellcyte.com)

Symbol: OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV.

## Safe Harbor Statement

THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM IS DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. STATEMENTS IN THIS NEWS RELEASE WHICH ARE NOT PURELY HISTORICAL FACT ARE FORWARD-LOOKING STATEMENTS THAT STATE BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE. EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS "ESTIMATE," "ANTICIPATE," "BELIEVE," "PLAN" OR "EXPECT" OR SIMILAR STATEMENTS ARE FORWARD-LOOKING STATEMENTS. RISKS AND UNCERTAINTIES FOR THE COMPANY INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH THE CLOSING OF THE CLOSING OF THE SHARE EXCHANGE AGREEMENT AND THE DEVELOPMENT AND FUNDING OF THE COMPANY CONSEQUENT THEREON, AS WELL AS THE RISKS SHOWN IN THE COMPANY'S MOST RECENT ANNUAL REPORT ON FORM 10-KSB AND ON FORM 10-QSB AND FROM TIME-TO-TIME IN OTHER PUBLICLY AVAILABLE INFORMATION REGARDING THE COMPANY. OTHER RISKS INCLUDE RISKS ASSOCIATED WITH THE REGULATORY APPROVAL PROCESS, COMPETITIVE COMPANIES, FUTURE CAPITAL REQUIREMENTS AND THE COMPANY'S ABILITY AND

LEVEL OF SUPPORT FOR ITS RESEARCH AND DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT THE COMPANY'S DEVELOPMENT EFFORTS WILL SUCCEED AND THE COMPANY WILL ULTIMATELY ACHIEVE COMMERCIAL SUCCESS.

THESE FORWARD-LOOKING STATEMENTS ARE MADE AS OF THE DATE OF THIS NEWS RELEASE, AND THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS, OR TO UPDATE THE REASONS WHY ACTUAL RESULTS COULD DIFFER FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS. ALTHOUGH THE COMPANY BELIEVES THAT THE BELIEFS, PLANS, EXPECTATIONS AND INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE REASONABLE, THERE CAN BE NO ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS WILL PROVE TO BE ACCURATE. INVESTORS SHOULD CONSIDER ALL OF THE INFORMATION SET FORTH HEREIN AND SHOULD ALSO REFER TO THE RISK FACTORS DISCLOSED IN THE COMPANY'S PERIODIC REPORTS FILED FROM TIME-TO- TIME WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION. THIS NEWS RELEASE HAS BEEN PREPARED BY MANAGEMENT OF THE COMPANY WHO TAKE FULL RESPONSIBILITY FOR ITS CONTENTS. EACH OF THE NASD, THE SEC AND THE OTCBB NEITHER APPROVES NOR DISAPPROVES OF THE CONTENTS OF THIS NEWS RELEASE. THIS NEWS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.